MCID: WLM013
MIFTS: 64

Wilms Tumor 1

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Cancer diseases, Fetal diseases

Aliases & Classifications for Wilms Tumor 1

MalaCards integrated aliases for Wilms Tumor 1:

Name: Wilms Tumor 1 57 75 29 6
Nephroblastoma 57 12 53 59 29 6 15 73
Wilms' Tumor 12 76 53
Wilms Tumor 57 59 44
Wt1 57 53 75
Bilateral Wilms Tumor 53 73
Renal Wilms' Tumor 12 15
Nonanaplastic Renal Wilm's Tumor 12
Nonanaplastic Kidney Wilms Tumor 73
Nonanaplastic Renal Wilms Tumor 12
Childhood Renal Wilms' Cancer 12
Childhood Kidney Wilms Tumor 73
Childhood Renal Wilms Tumor 12
Adult Renal Wilms' Tumor 12
Adult Kidney Wilms Tumor 73
Renal Embryonic Tumor 59
Wilms Tumor, Somatic 57
Adult Nephroblastoma 12
Wilms Tumor, Type 1 57
Renal Wilms Tumor 12
Wilms Tumor-1 13

Characteristics:

Orphanet epidemiological data:

59
nephroblastoma
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United Kingdom),1-5/10000 (Europe); Age of onset: Childhood; Age of death: any age;

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
genetic heterogeneity
majority of wilms tumors are sporadic
onset between 2-5 years
rare adult cases reported
5-10% of all wilms tumor are bilateral
21% of hereditary wilms tumor are bilateral
associated with several congenital malformation syndromes (wagr , abnormal urogenital development syndromes)
two-step mutation hypothesis (germline mutation followed by somatic mutation or two sequential somatic mutations)
loss of tumor suppressor gene
associated with several loci on chromosomes 11p15 (wt2, ), 16 (wt3, ), 17 (wt4, ), and 7 (wt5, ).



Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

OMIM 57 194070
Disease Ontology 12 DOID:2154 DOID:5176
MeSH 44 D009396
Orphanet 59 ORPHA654
MESH via Orphanet 45 D009396
UMLS via Orphanet 74 C0027708
ICD10 via Orphanet 34 C64
MedGen 42 C0027708

Summaries for Wilms Tumor 1

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 654Disease definitionNephroblastoma is the most frequent malignant renal tumor in children and is associated with an abnormal proliferation of cells that resemble the kidney cells of an embryo (metanephroma), leading to the term embryonal tumor.EpidemiologyThe annual incidence is estimated at about 1/10,000 births and it affects boys as well as girls.Clinical descriptionNephroblastoma mainly affects young children, between the ages 1 and 5 years, but 15% of nephroblastomas occur before the age of 1 year and 2% after the age of 8 years. Adult forms are very rare. An abdominal mass (unilateral in most cases) is frequently present. Patients sometimes experience abdominal pain (around 10% of cases), hypertension, fever (20% of cases), hematuria and anemia. The evolution of the disease is very rapid, with regional dissemination in the retroperitoneal space, lymph nodes, vessels (renal vein and inferior vena cava) and in the peritoneal cavity in cases of tumor effraction, and a strong likelihood of metastases in the lungs and liver.EtiologyNephroblastoma is sporadic in 99% of cases and, among these cases, 10% are associated with congenital anomalies (aniridia, hemihypertrophy, genitourinary defects) or form part of specific syndromes (Beckwith-Wiedemann, Denys-Drash, WAGR or Perlman syndromes; see these terms). Genetic anomalies found in different chromosomal regions, including 11p13 (containing the WT1 gene), 11p15.5 (containing the H19 gene), 16q, 1p, 1q and 17p, have been found within the tumors. Familial forms are very rare (1% of cases) and are transmitted in an autosomal dominant fashion.Diagnostic methodsDiagnosis is based on imagery, particularly CT or MRI scans. The concentration of urinary metabolites of catecholamines is normal. Analysis of the extent of the disease is also conducted using imagery (ultrasound and abdominal CT analyzing particularly the liver and contralateral kidney, and thoracic radiography and CT).Differential diagnosisDifferential diagnoses include other renal tumors in children such as mesoblastic nephroma (especially in infants), clear cell sarcoma, neuroblastoma (extremely rare in the kidney but may invade the kidney by contiguity), rhabdoid tumors (see these terms) and metanephric stromal tumors.Management and treatmentDisease management is multidisciplinary and may involve chemotherapy and surgery with or without radiotherapy. Chemotherapy enables preoperative reduction in tumor size and eradicates metastases. Surgery should be accomplished without tumor effraction, which usually means that total nephrectomy is required. Nephroblastoma can be confirmed on microscopic examination, which also allows the stage of the tumor in the kidney to be evaluated. This in turn determines the choice of post-operative chemotherapy. Radiotherapy is reserved for the most extensive cases or cases with the least favorable histology.PrognosisIn the majority of cases, the prognosis is favorable with a survival rate of over 90%. Adult forms have the same prognosis and should be treated following the same methods, even when adult patients tolerate chemotherapy less well than children (which may lead to a reduction in treatment and as a result a worse prognosis).Visit the Orphanet disease page for more resources.

MalaCards based summary : Wilms Tumor 1, also known as nephroblastoma, is related to frasier syndrome and leukemia, acute myeloid, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 1 is WT1 (Wilms Tumor 1), and among its related pathways/superpathways are BRCA1 Pathway and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Itraconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include children, kidney and myeloid, and related phenotypes are aniridia and hematuria

OMIM : 57 Wilms tumor is the most common renal tumor of childhood, occurring with an incidence of 1 in 10,000 and with a median age of diagnosis between 3 and 4 years of age. Wilms tumours are thought to develop from abnormally persistent embryonal cells within nephrogenic rests. Histologically, Wilms tumor mirrors the development of the normal kidney and classically consists of 3 cell types: blastema, epithelia, and stroma (summary by Slade et al., 2010). (194070)

UniProtKB/Swiss-Prot : 75 Wilms tumor 1: Embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms.

Disease Ontology : 12 A kidney cancer that affects the kidneys and typically located in children.

Wikipedia : 76 Wilms tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in children,... more...

Related Diseases for Wilms Tumor 1

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Related Disease Score Top Affiliating Genes
1 frasier syndrome 33.4 NR5A1 WT1 WT1-AS
2 leukemia, acute myeloid 31.4 MEG3 TP53 WT1 WT1-AS
3 wilms tumor 5 31.4 GPC3 H19 IGF2 POU6F2 WT1 WTAP
4 glioma 30.6 BRCA2 H19 MEG3 TP53
5 hepatocellular carcinoma 29.6 GPC3 H19 IGF2 IGF2-AS MEG3 TP53
6 cerebellar angioblastoma 11.3 TP53 WT1
7 ovarian cancer 1 11.3 BRCA2 TP53 WT1
8 meacham syndrome 11.3 WT1 WT1-AS
9 malignant ovarian surface epithelial-stromal neoplasm 11.3 BRCA2 TP53 WT1
10 ovary epithelial cancer 11.3 BRCA2 TP53 WT1
11 uterine corpus serous adenocarcinoma 11.2 BRCA2 TP53
12 wilms tumor 4 11.2
13 tetraploidy 11.2 BRCA2 TP53
14 46,xy partial gonadal dysgenesis 11.2 NR5A1 WT1
15 female reproductive endometrioid cancer 11.1 TP53 WT1
16 childhood multilocular cystic kidney neoplasm 11.1
17 mixed cell type kidney wilms' tumor 11.1
18 blastema predominant kidney wilms' tumor 11.1
19 epithelial predominant wilms' tumor 11.1
20 stromal predominant kidney wilms' tumor 11.1
21 sporadic breast cancer 11.0 BRCA2 CHEK2 TP53
22 hereditary breast ovarian cancer syndrome 11.0 BRCA2 CHEK2 TP53
23 li-fraumeni syndrome 2 11.0 CHEK2 TP53
24 li-fraumeni syndrome 10.9 BRCA2 CHEK2 TP53
25 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 10.9 IGF2 WT1 WT1-AS
26 simpson-golabi-behmel syndrome, type 1 10.9 GPC3 GPC4
27 muscle cancer 10.9 IGF2 TP53 WT1
28 marek disease 10.9 H19 TP53
29 meninges sarcoma 10.9 IGF2 TP53
30 leiomyosarcoma 10.8 IGF2 TP53 WT1
31 synchronous bilateral breast carcinoma 10.8 BRCA2 TP53
32 wilms tumor 6 10.8
33 wilms tumor 2 10.8 H19 KCNQ1DN
34 silver-russell syndrome due to an imprinting defect of 11p15 10.8 H19 IGF2
35 silver-russell syndrome due to 11p15 microduplication 10.8 H19 IGF2
36 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.7 H19 IGF2
37 hemihyperplasia, isolated 10.7 H19 IGF2 WT1
38 cerebral neuroblastoma 10.7 IGF2 TP53
39 gastrointestinal system cancer 10.7 GPC3 H19 IGF2 TP53
40 adamantinoma of long bones 10.7 BRCA2 H19 MEG3 TP53
41 hepatoblastoma 10.7 GPC3 H19 IGF2 TP53
42 vulva squamous cell carcinoma 10.6 MEG3 TP53
43 prostate disease 10.5 H19 IGF2-AS MEG3
44 simpson-golabi-behmel syndrome 10.5 GPC3 GPC4 IGF2
45 gallbladder cancer 10.5 H19 MEG3 TP53
46 osteogenic sarcoma 10.5 CHEK2 H19 MEG3 TP53
47 leukemia 10.5
48 perlman syndrome 10.5 DIS3L2 GPC3 GPC4
49 gastric cardia adenocarcinoma 10.5 H19 MEG3
50 fallopian tube adenocarcinoma 10.5 BRCA2 TP53

Graphical network of the top 20 diseases related to Wilms Tumor 1:



Diseases related to Wilms Tumor 1

Symptoms & Phenotypes for Wilms Tumor 1

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Kidneys:
nephroblastoma

Neoplasia:
nephroblastoma


Clinical features from OMIM:

194070

Human phenotypes related to Wilms Tumor 1:

59 32 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 aniridia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000526
2 hematuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000790
3 hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0000822
4 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
5 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
6 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
7 nephroblastoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002667
8 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
9 neoplasm of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0002896
10 neoplasm of the lung 59 32 occasional (7.5%) Occasional (29-5%) HP:0100526
11 neoplasm 59 Very frequent (99-80%)

UMLS symptoms related to Wilms Tumor 1:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.56 TP53 WT1 WTAP BRCA2 GPC3 IGF2
2 limbs/digits/tail MP:0005371 9.1 BRCA2 GPC3 IGF2 REST TP53 TRIP13

Drugs & Therapeutics for Wilms Tumor 1

Drugs for Wilms Tumor 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
6 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10
Hydroxyitraconazole Phase 4,Phase 3,Not Applicable
11 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
12
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
13
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
15
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
16
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
17
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
18
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
19
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 1 2353-33-5 451668
20
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
21
Morphine Approved, Investigational Phase 3 57-27-2 5288826
22
Cytarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 147-94-4 6253
23
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
24
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
25
Sulfamethoxazole Approved Phase 3 723-46-6 5329
26
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
27
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 21679-14-1, 75607-67-9 30751
28
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 3 24280-93-1 446541
30
Captopril Approved Phase 3 62571-86-2 44093
31
Palivizumab Approved, Investigational Phase 3 188039-54-5
32
Ribavirin Approved Phase 3 36791-04-5 37542
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
35
Caspofungin Approved Phase 3,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
36
Acyclovir Approved Phase 3 59277-89-3 2022
37
Histamine Approved, Investigational Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
38
Cyproheptadine Approved Phase 3 129-03-3 2913
39
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
40
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
41 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
43 Antimitotic Agents Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
46 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Etoposide phosphate Phase 3,Phase 2,Phase 1
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
3 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
4 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
5 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
6 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
8 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
9 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Completed NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
10 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
11 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
12 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
13 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3 FLAIMy - Fluda, Ida, Ara-C, Mylotarg
14 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3 gemtuzumab ozogamycin
15 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
16 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3 cyclosporine A;Mycophenolate mofetil;Ara-C;fludarabine;anti-lymphocyte globulin;cyclophosphamide
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
19 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
20 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
21 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
22 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
23 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
24 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3 conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
25 Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 Recruiting NCT02473146 Phase 2, Phase 3 Gemtuzumab ozogamicin (GO)
26 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
27 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
28 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
29 WT1 Peptid Vaccination in Carcinomas Unknown status NCT00153608 Phase 2
30 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Unknown status NCT00153582 Phase 2
31 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
32 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
33 Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma Unknown status NCT00965224 Phase 2
34 Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer Unknown status NCT02018458 Phase 1, Phase 2
35 Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Unknown status NCT01956630 Phase 1, Phase 2
36 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
37 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
38 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
39 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
40 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
41 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
42 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
43 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2 GM-CSF (Sargramostim)
44 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
45 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy Completed NCT01819558 Phase 1, Phase 2
46 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
47 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
48 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
49 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Completed NCT00405327 Phase 2
50 Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD Completed NCT02027805 Phase 1, Phase 2

Search NIH Clinical Center for Wilms Tumor 1

Cochrane evidence based reviews: wilms tumor

Genetic Tests for Wilms Tumor 1

Genetic tests related to Wilms Tumor 1:

# Genetic test Affiliating Genes
1 Wilms Tumor 1 29 BRCA2 GPC3 GPC4 H19 IGF2 WT1
2 Nephroblastoma 29

Anatomical Context for Wilms Tumor 1

The Foundational Model of Anatomy Ontology organs/tissues related to Wilms Tumor 1:

19
Children

MalaCards organs/tissues related to Wilms Tumor 1:

41
Kidney, Myeloid, Bone, Bone Marrow, T Cells, Lung, Liver

Publications for Wilms Tumor 1

Articles related to Wilms Tumor 1:

(show top 50) (show all 152)
# Title Authors Year
1
Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells. ( 29589053 )
2018
2
Immunoreactivity of Wilms tumor 1 (WT1) as an additional evidence supporting hemangiomatous rather than inflammatory origin in the etiopathogenesis of angiolymphoid hyperplasia with eosinophilia. ( 29445571 )
2018
3
Wilms' Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. ( 29414825 )
2018
4
Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction. ( 28994041 )
2018
5
Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay. ( 28573960 )
2018
6
Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. ( 29933069 )
2018
7
Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation. ( 29753838 )
2018
8
Description of mutation spectrum and polymorphism of Wilms' tumor 1 (WT1) gene in hypospadias patients in the Indonesian population. ( 29958641 )
2018
9
Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein. ( 28299466 )
2017
10
Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. ( 28067876 )
2017
11
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. ( 29100432 )
2017
12
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. ( 28054314 )
2017
13
Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. ( 28950074 )
2017
14
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. ( 28369773 )
2017
15
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. ( 27866185 )
2017
16
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification. ( 27922671 )
2017
17
Nucleotide Transition 390C-T in the Wilms' Tumor 1 Gene: A Risk Factor of Hypospadias? ( 28878596 )
2017
18
Transcription factor Wilms' tumor 1 regulates developmental RNAs through 3' UTR interaction. ( 28289143 )
2017
19
Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia. ( 28567073 )
2017
20
Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients. ( 28163010 )
2017
21
Molecular cloning of canine Wilms' tumor 1 for immunohistochemical analysis in canine tissues. ( 28603218 )
2017
22
Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation. ( 28673850 )
2017
23
Down-regulatory mechanism of mammea E/BB from Mammea siamensis seed extract on Wilms' Tumor 1 expression in K562 cells. ( 27193767 )
2016
24
Extremely High Expression of Antisense RNA for Wilms' Tumor 1 in Active Osteoclasts: Suppression of Wilms' Tumor 1 Protein Expression during Osteoclastogenesis. ( 27393793 )
2016
25
microRNA-361 targets Wilms' tumor 1 to inhibit the growth, migration and invasion of non-small-cell lung cancer cells. ( 27779659 )
2016
26
A novel functional variant in Wilms' tumor 1 (WT1) is associated with idiopathic non-obstructive azoospermia. ( 27990711 )
2016
27
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. ( 27252512 )
2016
28
Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience. ( 26725263 )
2016
29
Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. ( 27993090 )
2016
30
Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients. ( 28078270 )
2016
31
The Simultaneous Elevation of Oxidative Stress Markers and Wilms' Tumor 1 Gene during the Progression of Myelodysplastic Syndrome. ( 27980269 )
2016
32
Wilms' tumor 1 protein expression in endometrial adenocarcinoma and endometrial intra-epithelial neoplasia. ( 27062662 )
2016
33
Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. ( 27062571 )
2016
34
Wilms' tumor 1 (re)activation in evidence for both epicardial progenitor and endothelial cells for cardiovascular regeneration. ( 25863145 )
2015
35
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( 25772149 )
2015
36
Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. ( 25748047 )
2015
37
Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia. ( 25426668 )
2015
38
Wilms tumor 1 (WT1) protein: Diagnostic utility in pediatric tumors. ( 25881478 )
2015
39
Wilms' tumor 1 (WT1) protein expression in human developing tissues. ( 25858532 )
2015
40
Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population. ( 25841655 )
2015
41
Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm. ( 25932444 )
2015
42
Diagnostic Value of Wilms Tumor 1 and CD44 in Langerhans Cell Sarcoma: Case Series of 4 Patients. ( 25837753 )
2015
43
Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression. ( 25498507 )
2015
44
Oncofetal expression of Wilms' tumor 1 (WT1) protein in human fetal, adult and neoplastic skeletal muscle tissues. ( 25800978 )
2015
45
Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. ( 26252465 )
2015
46
Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. ( 24403445 )
2014
47
Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. ( 24667279 )
2014
48
Frequent hypermethylation of a CTCF binding site influences Wilms tumor 1 expression in Wilms tumors. ( 24534946 )
2014
49
High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. ( 24778040 )
2014
50
Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC. ( 25447528 )
2014

Variations for Wilms Tumor 1

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 1:

75
# Symbol AA change Variation ID SNP ID
1 WT1 p.Pro181Ser VAR_007739 rs2234584
2 WT1 p.Ser223Asn VAR_007740
3 WT1 p.Gly253Ala VAR_007741
4 WT1 p.Arg366Cys VAR_007745
5 WT1 p.Arg366His VAR_007746
6 WT1 p.His373Gln VAR_007747
7 WT1 p.Arg394Trp VAR_007750
8 WT1 p.Cys355Gly VAR_043799
9 WT1 p.Arg394Leu VAR_043807

ClinVar genetic disease variations for Wilms Tumor 1:

6
(show top 50) (show all 584)
# Gene Variation Type Significance SNP ID Assembly Location
1 WT1 NM_001198551.1(WT1): c.443delG (p.Gly148Valfs) deletion Pathogenic rs587776574 GRCh37 Chromosome 11, 32421513: 32421513
2 WT1 NM_001198551.1(WT1): c.242_258del17 (p.Asn81Ilefs) deletion Pathogenic rs587776573 GRCh38 Chromosome 11, 32417633: 32417649
3 WT1 NM_001198551.1(WT1): c.242_258del17 (p.Asn81Ilefs) deletion Pathogenic rs587776573 GRCh37 Chromosome 11, 32439179: 32439195
4 WT1 NM_001198551.1(WT1): c.443delG (p.Gly148Valfs) deletion Pathogenic rs587776574 GRCh38 Chromosome 11, 32399967: 32399967
5 WT1 NM_024426.4(WT1): c.1384C> T (p.Arg462Trp) single nucleotide variant Pathogenic rs121907900 GRCh37 Chromosome 11, 32413566: 32413566
6 WT1 NM_024426.4(WT1): c.1384C> T (p.Arg462Trp) single nucleotide variant Pathogenic rs121907900 GRCh38 Chromosome 11, 32392020: 32392020
7 WT1 NM_024426.4(WT1): c.1372C> T (p.Arg458Ter) single nucleotide variant Pathogenic rs121907909 GRCh37 Chromosome 11, 32413578: 32413578
8 WT1 NM_024426.4(WT1): c.1372C> T (p.Arg458Ter) single nucleotide variant Pathogenic rs121907909 GRCh38 Chromosome 11, 32392032: 32392032
9 WT1 NM_024426.4(WT1): c.1288C> T (p.Arg430Ter) single nucleotide variant Pathogenic rs121907906 GRCh37 Chromosome 11, 32414263: 32414263
10 WT1 NM_024426.4(WT1): c.1288C> T (p.Arg430Ter) single nucleotide variant Pathogenic rs121907906 GRCh38 Chromosome 11, 32392717: 32392717
11 WT1 NM_024426.4(WT1): c.531C> A (p.Tyr177Ter) single nucleotide variant Pathogenic rs121907911 GRCh37 Chromosome 11, 32456361: 32456361
12 WT1 NM_024426.4(WT1): c.531C> A (p.Tyr177Ter) single nucleotide variant Pathogenic rs121907911 GRCh38 Chromosome 11, 32434815: 32434815
13 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
14 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh38 Chromosome 13, 32329469: 32329470
15 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh37 Chromosome 13, 32914137: 32914137
16 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh38 Chromosome 13, 32340000: 32340000
17 GPC3 NM_004484.3(GPC3): c.361C> T (p.His121Tyr) single nucleotide variant Pathogenic rs122453119 GRCh37 Chromosome X, 132888180: 132888180
18 GPC3 NM_004484.3(GPC3): c.361C> T (p.His121Tyr) single nucleotide variant Pathogenic rs122453119 GRCh38 Chromosome X, 133754153: 133754153
19 GPC3 NM_004484.3(GPC3): c.1705G> A (p.Ala569Thr) single nucleotide variant Pathogenic rs122453120 GRCh37 Chromosome X, 132670190: 132670190
20 GPC3 NM_004484.3(GPC3): c.1705G> A (p.Ala569Thr) single nucleotide variant Pathogenic rs122453120 GRCh38 Chromosome X, 133536162: 133536162
21 GPC3 NM_004484.3(GPC3): c.1159C> T (p.Arg387Ter) single nucleotide variant Pathogenic rs122453121 GRCh37 Chromosome X, 132833930: 132833930
22 GPC3 NM_004484.3(GPC3): c.1159C> T (p.Arg387Ter) single nucleotide variant Pathogenic rs122453121 GRCh38 Chromosome X, 133699902: 133699902
23 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh37 Chromosome 13, 32914174: 32914174
24 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh38 Chromosome 13, 32340037: 32340037
25 BRCA2 NM_000059.3(BRCA2): c.7480C> T (p.Arg2494Ter) single nucleotide variant Pathogenic rs80358972 GRCh37 Chromosome 13, 32930609: 32930609
26 BRCA2 NM_000059.3(BRCA2): c.7480C> T (p.Arg2494Ter) single nucleotide variant Pathogenic rs80358972 GRCh38 Chromosome 13, 32356472: 32356472
27 BRCA2 NM_000059.3(BRCA2): c.9117G> A (p.Pro3039=) single nucleotide variant Pathogenic rs28897756 GRCh37 Chromosome 13, 32954050: 32954050
28 BRCA2 NM_000059.3(BRCA2): c.9117G> A (p.Pro3039=) single nucleotide variant Pathogenic rs28897756 GRCh38 Chromosome 13, 32379913: 32379913
29 BRCA2 NM_000059.3(BRCA2): c.145G> T (p.Glu49Ter) single nucleotide variant Pathogenic rs80358435 GRCh37 Chromosome 13, 32893291: 32893291
30 BRCA2 NM_000059.3(BRCA2): c.145G> T (p.Glu49Ter) single nucleotide variant Pathogenic rs80358435 GRCh38 Chromosome 13, 32319154: 32319154
31 BRCA2 NM_000059.3(BRCA2): c.5857G> T (p.Glu1953Ter) single nucleotide variant Pathogenic rs80358814 GRCh37 Chromosome 13, 32914349: 32914349
32 BRCA2 NM_000059.3(BRCA2): c.5857G> T (p.Glu1953Ter) single nucleotide variant Pathogenic rs80358814 GRCh38 Chromosome 13, 32340212: 32340212
33 WT1 NM_024426.4(WT1): c.108G> C (p.Pro36=) single nucleotide variant Conflicting interpretations of pathogenicity rs555140661 GRCh37 Chromosome 11, 32456784: 32456784
34 WT1 NM_024426.4(WT1): c.108G> C (p.Pro36=) single nucleotide variant Conflicting interpretations of pathogenicity rs555140661 GRCh38 Chromosome 11, 32435238: 32435238
35 WT1 NM_024426.4(WT1): c.330C> T (p.Pro110=) single nucleotide variant Benign rs1799925 GRCh37 Chromosome 11, 32456562: 32456562
36 WT1 NM_024426.4(WT1): c.330C> T (p.Pro110=) single nucleotide variant Benign rs1799925 GRCh38 Chromosome 11, 32435016: 32435016
37 GPC3 NM_004484.3(GPC3): c.1398G> A (p.Leu466=) single nucleotide variant Conflicting interpretations of pathogenicity rs745968470 GRCh37 Chromosome X, 132795773: 132795773
38 GPC3 NM_004484.3(GPC3): c.1398G> A (p.Leu466=) single nucleotide variant Conflicting interpretations of pathogenicity rs745968470 GRCh38 Chromosome X, 133661745: 133661745
39 WT1 NM_024426.4(WT1): c.1116T> C (p.Pro372=) single nucleotide variant Conflicting interpretations of pathogenicity rs151034312 GRCh37 Chromosome 11, 32417936: 32417936
40 WT1 NM_024426.4(WT1): c.1116T> C (p.Pro372=) single nucleotide variant Conflicting interpretations of pathogenicity rs151034312 GRCh38 Chromosome 11, 32396390: 32396390
41 WT1 NM_024426.4(WT1): c.1107A> G (p.Arg369=) single nucleotide variant Benign rs16754 GRCh37 Chromosome 11, 32417945: 32417945
42 WT1 NM_024426.4(WT1): c.1107A> G (p.Arg369=) single nucleotide variant Benign rs16754 GRCh38 Chromosome 11, 32396399: 32396399
43 WT1 NM_024426.4(WT1): c.1454G> A (p.Arg485Gln) single nucleotide variant Uncertain significance rs139893274 GRCh37 Chromosome 11, 32410704: 32410704
44 WT1 NM_024426.4(WT1): c.1454G> A (p.Arg485Gln) single nucleotide variant Uncertain significance rs139893274 GRCh38 Chromosome 11, 32389158: 32389158
45 WT1 NM_024426.4(WT1): c.1099-9T> C single nucleotide variant Benign/Likely benign rs5030274 GRCh38 Chromosome 11, 32396416: 32396416
46 WT1 NM_024426.4(WT1): c.1099-9T> C single nucleotide variant Benign/Likely benign rs5030274 GRCh37 Chromosome 11, 32417962: 32417962
47 WT1 NM_024426.4(WT1): c.930C> T (p.Asn310=) single nucleotide variant Likely benign rs775085343 GRCh38 Chromosome 11, 32417597: 32417597
48 WT1 NM_024426.4(WT1): c.930C> T (p.Asn310=) single nucleotide variant Likely benign rs775085343 GRCh37 Chromosome 11, 32439143: 32439143
49 WT1 NM_024426.4(WT1): c.774G> A (p.Glu258=) single nucleotide variant Likely benign rs878855087 GRCh38 Chromosome 11, 32428054: 32428054
50 WT1 NM_024426.4(WT1): c.774G> A (p.Glu258=) single nucleotide variant Likely benign rs878855087 GRCh37 Chromosome 11, 32449600: 32449600

Cosmic variations for Wilms Tumor 1:

9
(show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM21403 WT1 kidney,NS,Wilms tumour,unilateral c.1013C>A p.S338Y 11:32396289-32396289 27
2 COSM21967 WT1 kidney,NS,Wilms tumour,unilateral c.1180C>G p.R394G 11:32392020-32392020 27
3 COSM21401 WT1 kidney,NS,Wilms tumour,unilateral c.1084C>T p.R362* 11:32392717-32392717 27
4 COSM21445 WT1 kidney,NS,Wilms tumour,unilateral c.602G>A p.G201D 11:32428022-32428022 27
5 COSM21417 WT1 kidney,NS,Wilms tumour,unilateral c.1180C>T p.R394W 11:32392020-32392020 27
6 COSM21397 WT1 kidney,NS,Wilms tumour,unilateral c.1168C>T p.R390* 11:32392032-32392032 27
7 COSM21441 WT1 kidney,NS,Wilms tumour,unilateral c.901C>T p.R301* 11:32396401-32396401 27
8 COSM21398 WT1 kidney,NS,Wilms tumour,unilateral c.461T>C p.F154S 11:32428601-32428601 27
9 COSM21408 WT1 kidney,NS,Wilms tumour,unilateral c.1096C>T p.R366C 11:32392705-32392705 27
10 COSM21439 WT1 kidney,NS,Wilms tumour,unilateral c.797A>G p.N266S 11:32416490-32416490 27
11 COSM21971 WT1 kidney,NS,Wilms tumour,unilateral c.1112A>G p.K371R 11:32392689-32392689 27
12 COSM44510 TP53 kidney,NS,Wilms tumour,unilateral c.717C>G p.N239K 17:7674246-7674246 27
13 COSM5678 CTNNB1 kidney,NS,Wilms tumour,unilateral c.107A>C p.H36P 3:41224619-41224619 27
14 COSM5667 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>T p.S45F 3:41224646-41224646 27
15 COSM5664 CTNNB1 kidney,NS,Wilms tumour,unilateral c.121A>G p.T41A 3:41224633-41224633 27
16 COSM5663 CTNNB1 kidney,NS,Wilms tumour,unilateral c.133T>C p.S45P 3:41224645-41224645 27
17 COSM5692 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>A p.S45Y 3:41224646-41224646 27
18 COSM5689 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>G p.S45C 3:41224646-41224646 27
19 COSM13168 CTNNB1 kidney,NS,Wilms tumour,unilateral c.104T>C p.I35T 3:41224616-41224616 27
20 COSM250063 AMER1 kidney,NS,Wilms tumour,unilateral c.565C>T p.Q189* 23:64192722-64192722 27
21 COSM28715 AMER1 kidney,NS,Wilms tumour,unilateral c.85G>A p.A29T 23:64193202-64193202 27

Copy number variations for Wilms Tumor 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 24429 1 180300000 185800000 Microamplification CACNA1E Nephroblastoma

Expression for Wilms Tumor 1

Search GEO for disease gene expression data for Wilms Tumor 1.

Pathways for Wilms Tumor 1

Pathways related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.05 BRCA2 CHEK2 TP53
2 10.23 MEG3 TP53
3 9.32 CHEK2 TP53

GO Terms for Wilms Tumor 1

Biological processes related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.88 DIS3L2 GPC3 REST TP53 WT1
2 transcription by RNA polymerase II GO:0006366 9.85 NR5A1 POU6F2 REST TP53 TRIP13 WT1
3 positive regulation of transcription, DNA-templated GO:0045893 9.8 BRCA2 CHEK2 NR5A1 REST TP53 WT1
4 cellular response to drug GO:0035690 9.67 CHEK2 REST TP53
5 double-strand break repair GO:0006302 9.58 BRCA2 CHEK2 TRIP13
6 adrenal gland development GO:0030325 9.54 NR5A1 WT1
7 oocyte maturation GO:0001556 9.52 BRCA2 TRIP13
8 replicative senescence GO:0090399 9.51 CHEK2 TP53
9 positive regulation of male gonad development GO:2000020 9.46 NR5A1 WT1
10 sex determination GO:0007530 9.43 NR5A1 WT1
11 response to gamma radiation GO:0010332 9.33 BRCA2 CHEK2 TP53
12 negative regulation of female gonad development GO:2000195 9.26 NR5A1 WT1
13 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.13 BRCA2 CHEK2 TP53
14 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA2 CHEK2 TP53

Molecular functions related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparan sulfate proteoglycan binding GO:0043395 8.62 GPC3 GPC4

Sources for Wilms Tumor 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....